NCT00862342View on ClinicalTrials.gov

Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

June 30, 2012

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Bevacizumab (Avastin)

Bevacizumab plus chemotherapy (chemotherapy will be chosen by physician's decision)

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER